Cutaneous Melanoma Clinical Trial
Official title:
Fázis II, randomizált, kettős Vak vizsgálat a bőr metasztázisok kezelésére kálcium elektroporációval
Electroporation is a method that can facilitate transport of molecules across the cell
membrane and into the cell by means of electrical pulses. The method can be used with
molecules that normally have difficulty passing the cell membrane such as chemotherapy
(electrochemotherapy). Electrochemotherapy (ECT) is used in cancer therapy, where
chemotherapy is administered intratumoral or intravenous, then followed by electrical pulses
applied directly on the tumor. The chemotherapy accumulates in the cancer cells which results
in an increased cytotoxic effect. The most used chemotherapeutic drug used in
electrochemotherapy is bleomycin. Electrochemotherapy is a well-documented local treatment
form for especially cutaneous tumors. Today, the treatment is used mostly in palliative care
in more than 140 centres around Europe.
In vitro and in vivo studies have shown that the combination of calcium and electroporation
is an effective method in killing cancer cells without serious side effects.This new
combination opens the possibility of replacing bleomycin with calcium in treatments with
electroporation.
Calcium electroporation is a local treatment where calcium is administered intratumoral and
followed by electrical pulses applied on the tumor.
The preclinical studies have shown that there is a difference in sensitivity in tumor cells
and normal cells, as normal cells tolerate the treatment better than tumor cells (own data
manuscript in preparation). The studies have also shown that there is no cell injury by
calcium injection without electroporation, the investigators therefore expect that the
treatment only will cause minor side effects.
Calcium electroporation would be possible to use on patients for whom chemotherapy is
contradicted e.g. severe lung functions impairment, pregnant woman etc. Calcium
electroporation is a simple and unexpensive cancer treatment that does not involve any
administration of cytotoxic chemotherapy, and can be performed by surgeons, radiologists as
well as oncologists. Both electroporation equipment and calcium are already being used in the
clinic, so the treatment can easily be implemented.
Trial Design for Treatment of Cutaneous Metastases:
The current study is a randomized double blinded phase II study comparing the effect of
calcium electroporation with ECT with bleomycin on patients with cutaneous metastases of any
histology. As calcium and bleomycin are administered intratumoral, only small metastases from
0.5-3 cm will be treated. The treatments will be compared in tumor response and adverse
events. Treatment will be done in a palliative purpose.
Cancer patients with cutaneous involvement have often several metastases. A maximum of ten
metastases will be included per patient. One to six metastases (depending on the patient's
number of metastases) will be numbered 1-6 and randomized into one of two treatment arms
1. Intratumoral calcium followed by electroporation
2. Intratumoral bleomycin followed by electroporation Randomization will be performed
separately on each metastasis, so the patient may receive both treatments. Calcium and
bleomycin will be mixed into syringes labeled with numbers according to the metastases
and both treating doctor and patient will be blinded to the content of the syringes.
If the patient has more than six metastases, then one to four metastases will be used for
biopsy. The treatment of these metastases will be known, and biopsies will be performed
before and after treatment.
Biopsies will only be performed if the patient has more than six metastases. The metastases
used for biopsy will not be evaluated on response.
The treatment will be performed in local or general anesthesia depending on location and
number of metastases. Bleomycin/calcium will be administered intratumorally and immediately
after the electrode will be placed on the metastasis. The electric pulses are generated using
a cliniporator according to ESOPE (European Standard Operating Procedure of
Electrochemotherapy). The therapy is a once only treatment and the patients will be followed
up with regular clinical controls for six months. At follow up six months after treatment,
the randomization code for the one patient will be revealed. If the patient agrees, biopsies
will then be taken from an area treated with calcium and an area treated with bleomycin. Last
visit will be one year after treatment.
To identify the metastases at follow up visits, the metastases will be marked with a pen,
numbered and documented with clinical photos at baseline.
Randomization The metastases are randomized by block randomization and are done separately in
each patient. The randomization is performed by an extern unit, using the computer program
nQuery Adviser 7.0. The bleomycin and calcium are mixed and labeled by an extern unit, and
since both calcium and bleomycin are transparent and identical in volume, it is possible to
label the syringes in a manner to blind the treating doctor. The syringes are labeled with
numbers according to the metastases so syringe number "1" goes to metastasis number "1" and
so on. The randomization code is kept behind locked doors, and is not accessible to the
treating doctor. The randomization code is revealed for each patient after follow up, 6
months after treatment.
The randomization code can be revealed before completion of the investigation, if the
investigator believes that the treatment causes so serious unexpected events or reactions,
that a continuation of treatment is unacceptable.
As the randomization is done separately in each patient, code-break is possible for the
individual patient, without breaking the code of the other participants.
Dose In the preclinical study, the tumors were treated with isotonic calcium chloride
solution 168 mmol/L and with a volume equivalent to 0.5 x tumor volume, and this with good
effect. In another preclinical study the investigators have tested the effect of this dose in
different tumor types and saw variable results of the response rate. Some tumor types showed
slightly lower response at this dose (own data, manuscript in preparation). Because of this
experience the investigators have decided to increase the dose of calcium chloride, in this
trial, to 220 mmol/L.
Volume of calcium chloride is dependent on tumor volume. Smaller tumors should have bigger
volume per cm³, as smaller tumors are expected to have a bigger loss of injected medicine
into the surrounding tissue. The dose volume is calculated according to the "European
Standard Operating Procedure of the Electrochemotherapy (ESOPE)".
Calcium
Calcium chloride 220 mmol/L (9 mg/ml):
- Tumor < 0.5 cm³ - 1 ml/cm³ tumor volume
- Tumor > 0.5 cm³ - 0.5 ml/cm³ tumor volume Tumor volume = ab2π/6 (a = longest diameter, b
= longest diameter perpendicular to "a")
Bleomycin Both dose and volume of bleomycin is standard according to ESOPE
Bleomycin 1000 IU/ml:
- Tumor < 0.5 cm³ - 1 ml/cm³ tumor volume
- Tumor > 0.5 cm³ - 0,5 ml/cm³ tumor volume Tumor volume = ab²π/6 (a = longest diameter,
b= longest diameter perpendicular to "a")
Maximum of injected bleomycin per tumor will be 1500 IU and total dose per treatment 7500 IU.
Normal maximum limit for bleomycin is 15.000 IU/m² body surface area.
Bleomycin and calcium chloride are mixed and labeled according to current guidelines. The
mixtures will be used in a maximum of 6 hours after mixing.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05059444 -
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
|
||
Terminated |
NCT04042480 -
A Study of SGN-CD228A in Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT04020809 -
Neoadjuvant Atezolizumab in Cutaneous Melanoma
|
Phase 1 | |
Completed |
NCT03620019 -
Denosumab + PD-1 in Subjects With Stage III/ IV Melanoma
|
Phase 2 | |
Recruiting |
NCT03767348 -
Study of RP1 Monotherapy and RP1 in Combination With Nivolumab
|
Phase 2 | |
Withdrawn |
NCT05482074 -
Olaparib in Unresectable/Metastatic Melanoma With BRCA1/2
|
Phase 2 | |
Recruiting |
NCT05970497 -
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
|
Phase 1 | |
Completed |
NCT04551352 -
A Study of RO7293583 in Participants With Unresectable Metastatic Tyrosinase Related Protein 1 (TYRP1)-Positive Melanomas
|
Phase 1 | |
Recruiting |
NCT05544929 -
A Study of Safety and Efficacy of KFA115 Alone and in Combination With Pembrolizumab in Patients With Select Advanced Cancers
|
Phase 1 | |
Recruiting |
NCT05628883 -
Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma
|
Phase 1 | |
Terminated |
NCT04254107 -
A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer
|
Phase 1 | |
Recruiting |
NCT04830124 -
Nemvaleukin Alfa (ALKS 4230) Monotherapy in Patients With Advanced Cutaneous Melanoma or Advanced Mucosal Melanoma - ARTISTRY-6
|
Phase 2 | |
Recruiting |
NCT03699995 -
MoleMapper, Visiomed, and Confocal Microscopy in Screening Participants for Melanoma
|
N/A | |
Recruiting |
NCT06319196 -
Clear Me: Interception Trial to Detect and Clear Molecular Residual Disease in Patients With High-risk Melanoma
|
Phase 2 | |
Recruiting |
NCT05253872 -
The MELAcare Study: A New Method for Surveillance of Melanoma Patients
|
N/A | |
Recruiting |
NCT04706962 -
TH1902 in Patients With Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT04792463 -
Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome
|
||
Completed |
NCT00679289 -
Phase II Study of KW2871 Combined With High Dose Interferon-α2b in Patients With Metastatic Melanoma
|
Phase 2 | |
Recruiting |
NCT05669430 -
A Study of GV20-0251 in Patients With Solid Tumor Malignancies
|
Phase 1 | |
Recruiting |
NCT04702854 -
Evaluation of Ultrasound Biomicroscopy in the Local Staging of Cutaneous Melanoma
|
N/A |